Neurocrine Expects INGREZZA Revenue Growth in 2027

The drugmaker says double-digit volume gains should offset pricing pressure, though it has not set a numerical 2027 target.

Updated on Nov. 3, 2026 in Healthcare

Clean modern pharmaceutical production line with unlabeled white capsules moving along a stainless steel conveyor under even overhead light. — Neurocrine Biosciences reported $801 million in third-quarter INGREZZA sales, up 17%, and raised its 2026 sales projection to as much as $2.925 billion. AI Illustration. Upload story photo >

Neurocrine Biosciences reported INGREZZA net product sales of $801 million in the third quarter ended Sept. 30, up 17% from a year earlier. The company raised its 2026 INGREZZA net sales projection to $2.90 billion to $2.925 billion.

Why it matters

INGREZZA is a key revenue driver for Neurocrine, and the outlook signals that volume growth is expected to outpace pricing pressure in the coming year. Investors and patients alike will watch whether payer coverage and access remain stable.

Neurocrine's third-quarter INGREZZA sales of $801 million included a $20 million benefit from customer order timing, which is expected to reverse in the fourth quarter. The company has not yet set a numerical 2027 sales target.

The players

Neurocrine Biosciences

A San Diego-based biopharmaceutical company focused on neurological and endocrine disorders, and the maker of INGREZZA.

The details

Neurocrine attributed the 17% sales increase to double-digit volume growth and record prescriptions. For 2027, the company expects double-digit INGREZZA volume growth to offset mid- to high-single-digit net pricing pressure.

Sept. 30, 2026: Third quarter ended with INGREZZA sales of $801 million.
Nov. 2, 2026: Chief financial officer announced the 2027 revenue growth expectation on the earnings call.
Fourth quarter 2026: Expected reversal of the $20 million customer order timing benefit.
February 2027: Formal 2027 sales guidance is scheduled to be released.

Healthcare Landscape

Neurocrine's expectation of volume growth offsetting net price declines reflects the pressure branded drugmakers face under federal pricing policy such as the Inflation Reduction Act's Medicare negotiation provisions. The company's reliance on prescription volume shows how manufacturers are adapting to that environment.

Patients taking INGREZZA for tardive dyskinesia or Huntington's-related chorea should see continued access if payer coverage remains at least as strong as in 2026, as Neurocrine expects. Changes to net pricing could affect what insurers and patients pay over time.

The takeaway

Neurocrine's outlook shows that volume-driven growth can offset pricing headwinds for branded neurology drugs. Readers tracking the company should watch the February 2027 guidance release for a firmer sales target.

What happens next

Neurocrine is scheduled to release formal 2027 sales guidance in February 2027, and the reversal of the $20 million Q3 order timing benefit is expected in the fourth quarter of 2026.